Neoadjuvant treatment escalation approaches with dual anti-human epidermal growth factor receptor 2 (HER2) blockade have been proven effective in early-stage HER2-positive breast cancer, leading to an increase in pathological complete response (pCR) rates1,2. The gene discussed is ERBB2; the disease is breast cancer.